Can-Fite BioPharma Ltd. (ADR) share price logo

Can-Fite BioPharma Ltd. (ADR)

NASDAQ: CANF

Small Cap

$4.67

+1.70

(+57.24%)

as on

Can-Fite BioPharma Ltd. (ADR) Stock Performance

as on July 2, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $3.82
    $5.98
    downward going graph

    18.20%

    Downside

    28.05%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $2.56
    $21.00
    downward going graph

    45.18%

    Downside

    349.68%

    Upside

    downward going graph

Can-Fite BioPharma Ltd. (ADR) share price movements today

Previous Close
$2.97
Open
$4.99
Volume
37.5M
Day's Low - High
$3.82 - $5.98
52 Week Low - High
$2.56 - $21.00

Can-Fite BioPharma Ltd. (ADR) Historical Returns

1 Month Return
-8.33 %
3 Month Return
-3.88 %
1 Year Return
-85.72 %
3 Year Return
-95.16 %
5 Year Return
-99.36 %

Can-Fite BioPharma Ltd. (ADR) Stock Fundamentals & Key Indicators

Check Can-Fite BioPharma Ltd. (ADR) market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$5.9M

EPS (TTM)

-1.04

Dividend Yield

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

Return On Equity TTM

-178.24%

Can-Fite BioPharma Ltd. (ADR) vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Can-Fite BioPharma Ltd. (ADR) with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Can-Fite BioPharma Ltd. (ADR) image
Can-Fite BioPharma Ltd. (ADR)
NA$5.9M-99.36%NA0.00%NA
Revolution Medicines Inc. image
Revolution Medicines Inc.
BUY$41.0B460.55%NA0.00%NA
Alnylam Pharmaceuticals Inc. image
Alnylam Pharmaceuticals Inc.
BUY$40.2B77.34%75.4512.55%NA
Vertex Pharmaceuticals Inc. image
Vertex Pharmaceuticals Inc.
BUY$126.8B145.65%29.6635.51%NA
Regeneron Pharmaceuticals Inc. image
Regeneron Pharmaceuticals Inc.
BUY$66.4B8.51%15.4629.65%0.58%

Stock Returns calculator for Can-Fite BioPharma Ltd. (ADR) Stock including INR - Dollar returns

The Can-Fite BioPharma Ltd. (ADR) stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Can-Fite BioPharma Ltd. (ADR) investment value today

Current value as on today

₹24,974

Returns

-₹75,026

(-75.03%)

Returns from Can-Fite BioPharma Ltd. (ADR) Stock

-₹77,548 (-77.55%)

Dollar Impact

₹2,522 (+2.52%)

Indian Investors' Interest in Can-Fite BioPharma Ltd. (ADR) Stock

Search interest for Can-Fite BioPharma Ltd. (ADR) Stock has increased by 21% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:21% versus previous 30 day period

Can-Fite BioPharma Ltd. (ADR) Quarterly Profit & Loss

All numbers in Millions USD

Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Total Revenue
0
0
0
0
0
0
0
0
0
0
Gross Profit
0
0
0
0
0
0
0
0
0
0
Operating Income
-2
-1
-1
-1
-2
-2
-2
-2
-2
-2
EBITDA
-2
-1
-1
-1
-2
-2
-2
-2
-2
-2
Interest Expense
0
-
0
0
-
-
-
-
-
-
Depreciation
-
-
-
-
-
-
-
-
-
-
Income Before Tax
-2
-1
-1
-1
-1
-1
-1
-1
-2
-2
Income Tax Expense
0
0
0
0
-
-
-
-
-
-
Net Income
-2
-1
-1
-1
-1
-1
-1
-1
-2
-2
Net Profit Margin
-1218.37%
-852.04%
-898.98%
-1065.81%
-1252.22%
-1252.22%
-1095.81%
-1095.81%
-2413.86%
-2413.86%

Can-Fite BioPharma Ltd. (ADR) Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
0
0
3
2
0
0
0
0
0
0
Gross Profit
0
0
3
2
0
0
0
0
0
0
Operating Income
-8
-7
-5
-12
-14
-12
-10
-8
-8
-10
EBITDA
-8
-7
-6
-11
-14
-12
-10
-8
-8
-10
Interest Expense
0
1
1
0
0
0
0
0
0
0
Depreciation
-
0
0
0
0
0
0
0
0
0
Income Before Tax
-6
-4
-6
-12
-14
-12
-10
-7
-7
-9
Income Tax Expense
0
0
0
0
0
0
0
0
-
-
Net Income
-6
-4
-6
-12
-14
-12
-10
-7
-7
-9
Net Profit Margin
-4069.33%
-588.18%
-172.02%
-621.31%
-1892.92%
-1476.55%
-1263.70%
-1027.46%
-1169.14%
-2426.67%

Can-Fite BioPharma Ltd. (ADR) Quarterly Cash Flow

All numbers in Millions USD

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Net Income
-1
-1
-1
-1
-1
-1
-1
-2
-2
Operating Cash Flow
0
0
-2
-2
-2
-1
-1
-2
-2
Investing Cash Flow
-
-
-
2
2
-1
-1
1
1
Financing Cash Flow
-
-
-
-
-
3
3
1
1
Change in Cash
0
0
0
0
4
-4
-
-
-

Can-Fite BioPharma Ltd. (ADR) Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-4
-6
-12
-14
-12
-10
-7
-7
-9
Operating Cash Flow
-9
-4
-10
-12
-9
-10
-8
-7
-9
Investing Cash Flow
0
0
0
0
-14
9
0
1
0
Financing Cash Flow
4
4
10
17
20
20
9
6
9
Change in Cash
-5
0
0
5
-3
-1
1
0
0

Can-Fite BioPharma Ltd. (ADR) News & Key Events

  • img

    Today's Timeline - 18 November

    Tue, 07:51 PM

    -

    Can-Fite BioPharma announces patient survival of 9 years with Namodenoson, boosting stock by 51.27% in pre-market trading.

Insights on Can-Fite BioPharma Ltd. (ADR)

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 600.1% return, outperforming this stock by 695.3%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Revolution Medicines, Inc. Common Stock has given 407.7% return, outperforming this stock by 493.4%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 3 quarters, 179.0K → 101.0K (in $), with an average decrease of 21.8% per quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 year, CANF stock has moved down by -85.7%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 3 quarters, -1.96M → -2.43M (in $), with an average decrease of 12.2% per quarter

About Can-Fite BioPharma Ltd. (ADR)

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, It offers cannabinoids for treatment of conditions associated with elevated expression of the A3 adenosine receptors. Further, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.
OrganisationCan-Fite BioPharma Ltd. (ADR)
Headquarters26 Ben Gurion Street, Ramat Gan, Israel, 5257346
IndustryBiotechnology
CEOMr. Motti Farbstein
E-voting on sharesClick here to vote

Key Management of Can-Fite BioPharma Ltd. (ADR)

Name

Title

Dr. Sari Fishman Ph.D.

Vice President of Business Development

Dr. Stephen A. Harrison FACP, M.D.

Member of Clinical Advisory Board & Consulting Chief Medical Officer

Dr. Pnina Fishman Ph.D.

Founder, Chief Scientific Officer & Executive Chairperson

Mr. Motti Farbstein

CEO, CFO, Financial & Operating Officer

FAQs

What is Can-Fite BioPharma Ltd. (ADR) share price today?

Can-Fite BioPharma Ltd. (ADR) share price today is $4.67 as on at the close of the market. Can-Fite BioPharma Ltd. (ADR) share today touched a day high of $5.98 and a low of $3.82.

What is the 52 week high and 52 week low for Can-Fite BioPharma Ltd. (ADR) share?

Can-Fite BioPharma Ltd. (ADR) share touched a 52 week high of $21 on and a 52 week low of $2.56 on . Can-Fite BioPharma Ltd. (ADR) stock price today i.e. is closed at $4.67,which is 77.76% down from its 52 week high and 82.42% up from its 52 week low.

What is Can-Fite BioPharma Ltd. (ADR)'s market capitalisation today?

Can-Fite BioPharma Ltd. (ADR) market capitalisation is $0.00T as on .

How to invest in Can-Fite BioPharma Ltd. (ADR) Stock (CANF) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Can-Fite BioPharma Ltd. (ADR) on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Can-Fite BioPharma Ltd. (ADR) Shares that will get you 0.3212 shares as per Can-Fite BioPharma Ltd. (ADR) share price of $4.67 per share as on July 2, 2026 at 1:29 am IST.

What is the minimum amount required to buy Can-Fite BioPharma Ltd. (ADR) Stock (CANF) from India?

Indian investors can start investing in Can-Fite BioPharma Ltd. (ADR) (CANF) shares with as little as ₹95.2475 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹952.48 in Can-Fite BioPharma Ltd. (ADR) stock (as per the Rupee-Dollar exchange rate as on ). Based on Can-Fite BioPharma Ltd. (ADR) share’s latest price of $4.67 as on July 2, 2026 at 1:29 am IST, you will get 2.1413 shares of Can-Fite BioPharma Ltd. (ADR). Learn more about fractional shares .

What are the returns that Can-Fite BioPharma Ltd. (ADR) has given to Indian investors in the last 5 years?

Can-Fite BioPharma Ltd. (ADR) stock has given -99.36% share price returns and 26.8% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?